Tirzepatide ���子背景与靶点 — Quick Reference

By Editorial Desk · published 2025-11-23 · last reviewed 2026-01-12 · Topic

incretin raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.

Reviewed 2026-01-12. Anything still debated is marked as such rather than presented as settled.

Tirzepatide 分子背景与靶点

当前公开资料把 tirzepatide 归为肠促胰素类受体双重激动剂。它并非激素天然变体，而是经过序列改造的工程化肽。其分子量、等电点与疏水性等基础参数已在药典和化学数据库中收录，可作为分析检测和质量研究的参照。

Tirzepatide 是一种由 39 个氨基酸组成的合成肽，分子结构上以 GIP 序列为骨架并引入脂肪酸侧链修饰，使其能够同时与葡萄糖依赖性促胰岛素多肽（GIP）受体和胰高血糖素样肽-1（GLP-1）受体结合。这种双重激动特性使它在同类肽类药物中区别于选择性 GLP-1 受体激动剂。该分子最早由一家制药公司在 2010 年代报道，随后进入糖尿病与体重管理领域的临床研究。

Background and Molecular Development

Structural work on the molecule centers on a C20 fatty diacid moiety attached through a linker to the peptide backbone. This side chain promotes reversible binding to serum albumin, which slows renal clearance and supports a prolonged action profile. The peptide backbone incorporates aminoisobutyric acid substitutions that limit recognition by digestive enzymes. Together these modifications produce a molecule that is stable enough for subcutaneous delivery but still dependent on careful manufacturing control. Analytical characterization of the active pharmaceutical ingredient typically follows the conventions used for other synthetic peptides.

Tirzepatide is a synthetic peptide composed of 39 amino acids. It acts as a dual agonist at two incretin receptors, the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. The molecule was designed by modifying the native sequence of glucose-dependent insulinotropic polypeptide to improve metabolic stability and extend its circulation time. Its structure includes several non-natural amino acid residues and a fatty acid side chain. These features distinguish it from earlier single-receptor incretin analogs studied in the same period.

Tirzepatide at a glance

Background and Dual Receptor Pharmacology

Clinical development proceeded through large phase 3 programmes in type 2 diabetes and in obesity or overweight with at least one weight-related comorbidity. Regulatory approvals followed in several jurisdictions for both indications. Weekly subcutaneous dosing reflects an elimination half-life of roughly five days. Open questions include the durability of metabolic effects after treatment stops, long-term cardiovascular and hepatic outcomes beyond completed trials, and whether the dual mechanism confers benefits independent of total receptor occupancy. Published literature continues to expand on these points. Substantial uncertainty remains about interindividual variability in response.

Tirzepatide is a synthetic linear peptide of 39 amino acids that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Its sequence derives from native GIP but incorporates non-natural residues and a C20 fatty diacid moiety linked to a lysine side chain. The lipophilic chain promotes albumin binding, which slows renal clearance and extends circulation time. The unmodified peptide has a molecular formula of C225H348N48O68 and a molecular mass near 4,813 daltons.

Receptor activation by tirzepatide raises intracellular cyclic AMP through Gs-coupled signalling at both targets. At the GLP-1 receptor the downstream effect includes glucose-dependent insulin release, suppressed glucagon secretion, delayed gastric emptying, and reduced appetite signalling in the hypothalamus. GIP receptor engagement adds insulinotropic activity and appears to influence lipid handling in adipose tissue. Because both receptors are stimulated at the same time, the pharmacological profile differs from that of selective GLP-1 receptor agonists, and the relative contribution of each arm remains an area of active investigation.

Related pages on this site

• Modern primer
• Efficient trends
• Practical handbook
• Regional digest
• Automated update
• Scalable casebook
• Reliable overview
• Quality dataset

Molecular Basis and Receptor Pharmacology

At the receptor level, the compound binds both GIP and GLP-1 receptors and triggers downstream signalling that raises cyclic AMP in target cells. GLP-1 receptor activation is associated with glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. GIP receptor activation contributes effects that are less completely characterised, and how much each receptor adds to the overall clinical response is still an open question. The two pathways appear to interact in a complementary rather than a purely additive way.

An extended fatty diacid moiety promotes binding to serum albumin, which slows renal clearance and extends the circulating half-life to roughly five days. That property supports once-weekly administration and largely explains the dosing interval described in clinical reports. Published data come mainly from large randomised programmes that evaluated glycaemic control and body weight over periods of many months. Long-term outcomes beyond those trial windows, including what happens after treatment stops, remain an active area of investigation.

Tirzepatide is a synthetic peptide built from thirty-nine amino acids. Its sequence is derived from native glucose-dependent insulinotropic polypeptide, or GIP, with several non-natural residues and a fatty diacid side chain attached through a linker. The molecule behaves as a dual agonist at two incretin receptors, GIP and GLP-1, instead of targeting a single receptor. This dual engagement separates it from earlier single-receptor incretin compounds and underpins most of its reported pharmacological activity.

Dual Incretin Receptor Agonism

Tirzepatide is a synthetic peptide that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The molecule contains 39 amino acids and features a C20 fatty diacid moiety attached via a linker, which promotes albumin binding and extends its circulating half-life. Its sequence incorporates non-natural amino acids and modifications that reduce susceptibility to degradation by dipeptidyl peptidase-4. This dual receptor activity distinguishes it from selective GLP-1 receptor agonists.

The GIP receptor is expressed in pancreatic islets, adipose tissue, and the central nervous system, while GLP-1 receptors are found in pancreatic islets, the gastrointestinal tract, and the brain. Activation of both receptors can enhance glucose-dependent insulin secretion and reduce glucagon release. The relative contribution of each receptor to the overall pharmacological effect remains an area of ongoing investigation. Preclinical studies suggest that GIP receptor agonism may modulate appetite and energy balance, but the precise mechanisms in humans are not fully established.

Background And Receptor Pharmacology

Tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor, making it a dual agonist rather than a selective agent. Engagement of the GLP-1 receptor is linked to glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. The relative contribution of the GIP arm remains an active research question; proposed roles include improved insulin sensitivity and altered adipose tissue handling. Receptor occupancy studies suggest the molecule interacts with both targets at circulating concentrations achieved during therapy.

Development began in the 2010s, when researchers modified a GIP-based scaffold to add GLP-1 activity and then attached the fatty diacid to lengthen its half-life. Clinical evaluation proceeded through large phase 3 programmes in type 2 diabetes and in obesity, and regulators in the United States cleared the compound for type 2 diabetes in 2022 and for chronic weight management in 2023. Several cardiovascular and metabolic outcome studies are still reporting, so the picture of long-term benefit and risk is incomplete. Approvals in other regions followed on different timelines.

Tirzepatide is a synthetic peptide of 39 amino acids that carries a C20 fatty diacid side chain attached through a linker. Its molecular formula is C225H348N48O68, and its molecular weight is about 4813 daltons. The compound belongs to the incretin mimetic class and is administered by subcutaneous injection. The fatty acid chain promotes binding to serum albumin, which slows renal clearance and extends the circulation time of the molecule. It was identified during screening of sequences derived from glucose-dependent insulinotropic polypeptide.

Notes from published material

Bill 28 imposes a contract on CUPE, and makes it illegal to strike, setting fines of $4000 for workers. The bill invokes the notwithstanding clause, shielding it from being struck down by the courts by allowing the bill to operate despite the right to collective bargaining granted by the Canadian Charter of Rights and Freedoms. The legislation was widely condemned, including by opposition parties, the Canadian Civil Liberties Association, Prime Minister Justin Trudeau, Minister of Justice and Attorney General of Canada David Lametti, the Ontario Bar Association, and other unions including those which had previously endorsed the PC Party. Despite the government's bill, CUPE went on strike anyway, resulting in province-wide school closures and protests in support of education workers. The government challenged CUPE at the Ontario Labour Relations Board. On November 7, 2022, Ford announced that he would rescind Bill 28 and that he would resume negotiations with CUPE. Following the strike, Ford said he did not regret his use of the notwithstanding clause in imposing the contract and said that it helped both sides "come to their senses". Following Paul Calandra's appointment as minister of education in 2025, he began appointing supervisors to take over several of Ontario's school boards. The government's Bill 33 would give the education ministry more power over school boards. In early 2026, Calandra announced the "Putting Student Achievement First Act," which includes many education reforms.

== Biography == Partha Mitra received his PhD in theoretical physics from Harvard University under the guidance of Bertrand Halperin in 1993. He was a member of the Theoretical Physics Department at Bell Laboratories from 1993 to 2003, and an assistant professor in Theoretical Physics at Caltech from 1996 before moving to Cold Spring Harbor Laboratory in 2003 where he is a Crick-Clay professor of biomathematics. Professor Mitra also holds adjunct positions in the NYU School of Medicine and Weill Cornell Medical College.

== Safety == In vivo dermal sensitization studies according to OECD 429 confirmed EDC is a strong skin sensitizer, showing a response at <0.01 wt% in the Local Lymph Node Assay (LLNA) placing it in Globally Harmonized System of Classification and Labelling of Chemicals (GHS) Dermal Sensitization Category 1A. Thermal hazard analysis by differential scanning calorimetry (DSC) shows EDC poses minimal explosion risks.

=== Double network hydrogels === Similar to the previous study, double network hydrogels are used. They are composed of two kinds of hydrophilic polymers. At 6 weeks of implantation, the samples compared to those without treatment showed biodegradable properties. When using poly(2-acrylamide-2-methyl-propane sulfonic acid)/poly(N,N'-dimethyl acrylamide) or PAMPS/PDMAAm ultimate stress and tangent modulus increased. However, when using bacterial cellulose and gelatin, it showed a decrease of ultimate stress and it did not meet the requirements of artificial cartilage.

Hyaline cartilage is the glass-like (hyaline) and translucent cartilage found on many joint surfaces. It is also most commonly found in the ribs, nose, larynx, and trachea. Hyaline cartilage is pearl-gray in color, with a firm consistency and has a considerable amount of collagen. It contains no nerves or blood vessels, and its structure is relatively simple.

Sources: en.wikipedia.org

Background from the literature

=== Protists === Hydroxyproline is also found in the walls of oomycetes, fungus-like protists related to diatoms. Phytophthora cactorum specifically produces a pathogenic protein containg 4-hydroxyproline.

==== Deposition ==== The extracellular matrix of bone is laid down by osteoblasts, which secrete both collagen and ground substance. These cells synthesise collagen alpha polypeptide chains and then secrete collagen molecules. The collagen molecules associate with their neighbors and crosslink via lysyl oxidase to form collagen fibrils. At this stage, they are not yet mineralized, and this zone of unmineralized collagen fibrils is called "osteoid". Around and inside collagen fibrils calcium and phosphate eventually precipitate within days to weeks becoming then fully mineralized bone with an overall carbonate substituted hydroxyapatite inorganic phase. In order to mineralise the bone, the osteoblasts secrete alkaline phosphatase, some of which is carried by vesicles. This cleaves the inhibitory pyrophosphate and simultaneously generates free phosphate ions for mineralization, acting as the foci for calcium and phosphate deposition. Vesicles may initiate some of the early mineralization events by rupturing and acting as a centre for crystals to grow on. Bone mineral may be formed from globular and plate structures, and via initially amorphous phases.

The standard electrode potential for reduction of Fl2+ ion to metallic flerovium is estimated to be around +0.9 V, confirming the increased stability of flerovium in the neutral state. In general, due to relativistic stabilization of the 7p1/2 spinor, Fl2+ is expected to have properties intermediate between those of Hg2+ or Cd2+ and its lighter congener Pb2+.

Early drafts of the European Union's General Data Protection Regulation in 2016 included an explicit statement that this right exists. Industry experts noted that this is an unsolved problem with no solution in sight. Regulators argued that nevertheless the harm is real: if the problem has no solution, the tools should not be used. DARPA established the XAI ("Explainable Artificial Intelligence") program in 2014 to try to solve these problems. Several approaches aim to address the transparency problem. SHAP enables to visualise the contribution of each feature to the output. LIME can locally approximate a model's outputs with a simpler, interpretable model. Multitask learning provides a large number of outputs in addition to the target classification. These other outputs can help developers deduce what the network has learned. Deconvolution, DeepDream and other generative methods can allow developers to see what different layers of a deep network for computer vision have learned, and produce output that can suggest what the network is learning. For generative pre-trained transformers, Anthropic developed a technique based on dictionary learning that associates patterns of neuron activations with human-understandable concepts.

=== Prophecy === In Tales of the Green Lantern Corps Annual #2 (1986), a prophecy narrated to Abin Sur suggests that Mogo will be the last Green Lantern. In a battle with the "Empire of Tears", Ranx the Sentient City will explode a bomb in Mogo's core, killing him and ending the Green Lantern Corps. The Sinestro Corps attack Mogo with Ranx, who started to drill into the planet, with the intention of planting the blink bomb. It was revealed that Mogo is the one who guides the rings of deceased Lanterns to find new replacements and that if he should die, the Corps would be unable to recruit members in this manner. Thanks to the efforts of Sodam Yat, as well as a change in the Book of Oa permitting the Lanterns to use lethal force against the Sinestro Corps, Ranx is destroyed and the Sinestro Corps are driven from Mogo.

Sources: en.wikipedia.org

Reference notes

== Literature == Ashle, Steven (June 2002). "Divide and Vitrify" (PDF). Scientific American. 286 (6): 17–19. Bibcode:2002SciAm.286f..17A. doi:10.1038/scientificamerican0602-17. Retrieved May 10, 2015. Lovgren, Stefan. "Corpses Frozen for Future Rebirth by Arizona Company", March 2005, National Geographic

=== Bifurcated and over-coordinated hydrogen bonds in water === A single hydrogen atom can participate in two hydrogen bonds. This type of bonding is called "bifurcated" (split in two or "two-forked"). It can exist, for instance, in complex organic molecules. It has been suggested that a bifurcated hydrogen atom is an essential step in water reorientation. Acceptor-type hydrogen bonds (terminating on an oxygen's lone pairs) are more likely to form bifurcation (it is called overcoordinated oxygen, OCO) than are donor-type hydrogen bonds, beginning on the same oxygen atom's hydrogen atoms.

Compounds and their metabolites need to be removed from the body via excretion, usually through the kidneys (urine) or in the feces. Unless excretion is complete, accumulation of foreign substances can adversely affect normal metabolism. There are three main sites where drug excretion occurs. The kidney is the most important site and it is where products are excreted through urine. Biliary excretion or fecal excretion is the process that initiates in the liver and passes through to the gut until the products are finally excreted along with waste products or feces. The last main method of excretion is through the lungs (e.g. anesthetic gases). Excretion of drugs by the kidney involves 3 main mechanisms:

== Bioequivalence == In determining bioequivalence between two products such as a commercially available Branded product and a potential to-be-marketed Generic product, pharmacokinetic studies are conducted whereby each of the preparations are administered in a cross-over study (sometimes parallel study, when a cross-over study is not feasible) to volunteer subjects, generally healthy individuals but occasionally in patients. Serum/plasma samples are obtained at prescribed times and assayed for parent drug (or occasionally metabolite) concentration. Occasionally, blood concentration levels are neither feasible or possible to compare the two products (e.g. inhaled corticosteroids), then pharmacodynamic endpoints rather than pharmacokinetic endpoints (see below) are used for comparison. For a pharmacokinetic comparison, the plasma concentration data are used to assess key pharmacokinetic parameters such as area under the curve (AUC), peak concentration (Cmax), time to peak concentration (tmax), and absorption lag time (tlag). Testing should be conducted at several different doses, especially when the drug displays non-linear pharmacokinetics. In addition to data from bioequivalence studies, other data may need to be submitted to meet regulatory requirements for bioequivalence. Such evidence may include:

Sources: en.wikipedia.org

Frequently asked questions